✻ About us

Caarlogic Biomed

Caarlogic Biomed is committed to accelerating the applications of cell-based therapies to improve patient outcomes. Our primary goal is to address significant drawbacks in the current treatment approach, particularly in terms of effectiveness and safety.

We are diligently working on an innovative portfolio that aims to make the full benefits of CAR-T cell therapy and immune cytokines more accessible to patients with hematological malignancies, solid cancers, and autoimmune diseases.

Vision

Our vision is to brew a new hope within Caarlogic Biomed for patients with various cancers and autoimmune diseases.

Our comprehensive strategy is that it initially employs off-the-shelf, allogeneic CAR+ cells for induction therapy, followed by autologous CAR-T for consolidation and, ultimately, the augmentation of immune cell persistence with immunocytokines. This multifaceted approach optimizes therapeutic outcomes and marks the beginning of a new era in cancer immunotherapy.

History

Reorg to focus on cell & immunotherapy

Resided into National Biotechnology Research Park, Nangang Dist.,Taipei(330m2)

Leadership

Caarlogic Biomed, founded and led by Dr. Lo, MD, and Dr. Lin, MD, is unwavering in its mission to advance Taiwan’s biomedicine. Dr. Luo has long observed the medical field, with a particular focus on regenerative medicine. Dr. Lin has been researching CAR-T at Carl June’s Lab at the University of Pennsylvania. Together with a scientific team derived from the National Taiwan University Hospital, Caarlogic Biomed has developed pioneering technologies related to cell and immunotherapies that will drive the future. Working in tandem, our administrative and finance teams ensure strict adherence to regulations while propelling our company toward its goal of becoming a publicly traded entity.

羅浚晅 醫師
Chun-Hsuan Lo, MD.

董事長 Chairman

✤ Experience

Dual degrees in Medicine and Law, graduated from National Taiwan University

✤ Special field

Dr. Lo is a versatile leader with expertise spanning healthcare, law, and business.

He is the current president of the Taiwan Physicians’ Union and a standing director of the Taiwan Medical Law Association. His contributions to healthcare policy are evident in his roles as a committee member for the Ministry of Health and Welfare's Patient Autonomy Rights Act and the Over-the-Counter Drug Advisory Committee.

Additionally, he has served as the spokesperson for the Chinese Medical Association and is the incoming secretary-general of Rotary International District 3490.

Chien-ting Lin
林建廷 醫師
Chien-Ting Lin, MD.

執行長 Chief Executive Officer

✤ Experience
M.D., National Taiwan University

✤ Special field

Dr. Lin possesses more than 15 years of clinical experience in hematology-oncology and transplantation at National Taiwan University Hospital. Dr. Lin has a proven track record in designing and conducting innovative clinical trials, not only company-sponsored trials but also investigator-initiated trials.

Dr. Lin’s expertise in CAR-T cell therapy was significantly enhanced through a fellowship under the mentorship of Dr. Carl June at University of Pennsylvania from 2014 to 2015. As a pioneer in this field in Taiwan, Dr. Lin has made significant contributions to the advancement of CAR-T cell therapy and have been honored with multiple national and international awards. Dr. Lin’s innovative work has also led to several patents in the field of cell therapy.

As a former member of the TFDA Regenerative Medicine Advisory Committee, Dr. Lin has a deep understanding of regulatory requirements. These experiences are highly invaluable in leading Caarlogic Biomed.

Scientific advisors

Caarlogic Biomed boasts a team of esteemed scientific advisors renowned for their expertise in cancer biology, tumor microenvironment, cell therapy, genetics, epigenetics, and clinical trials. Their in-depth knowledge and experience make them instrumental in driving groundbreaking advancements in biomedicine.

吳尚儒 醫師/博士
Shang-Ju Wu MD., PhD.

科學顧問 Scientific advisor

✤ Experience

M.D., National Taiwan University

Ph.D. in Clinical Medicine, College of Medicine, National Taiwan University

✤ Current Position

Attending Physician, Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital

Associate Professor, Department of Internal Medicine, College of Medicine, National Taiwan University

✤ Special field

Dr. Wu is a dedicated healthcare professional specializing in hematologic malignancies. With a strong foundation in medical education and extensive clinical experience, Dr. Wu is committed to providing state-of-the-art care for patients battling blood cancers.

 

Key Areas of Expertise:

Hematologic Malignancies:

Acute and chronic leukemias, lymphomas, multiple myeloma

 

Transplantation Medicine:

Allogeneic and autologous hematopoietic stem cell transplantation (HSCT), Graft-versus-host disease (GVHD) prevention and management

 

Cellular Therapies:

Chimeric antigen receptor (CAR)-T cell therapy

 

Clinical Trials and Research:

Dr. Wu is actively involved in clinical trials and research to advance the treatment of hematologic malignancies. By participating in cutting-edge studies, Dr. Wu aims to bring innovative therapies to patients and improve outcomes.

Bear Huang
黃傳翔 醫師/博士
Chuan-Hsiang Bear Huang, MD., PhD.

科學顧問 Scientific advisor

✤ Experience

M.D., National Taiwan University
Ph.D. in Immunology and Biophysics, Johns Hopkins University

✤ Current Position

Associate Professor of Pathology & Cell Biology, Center for Cell Dynamics, Johns Hopkins University School of Medicine

✤ Special field

Dr. Huang is a dedicated researcher specializing in cancer cell biology in the Department of Pathology at Johns Hopkins University. With a strong foundation in medical science and a passion for understanding the complexities of cancer, Dr. Huang is committed to advancing the field of oncology and improving patient outcomes.

Dr. Huang 's research focuses on unraveling the molecular mechanisms underlying cancer development, progression, and metastasis. By studying the intricate interplay between cells within the tumor microenvironment, Dr. Huang aims to identify novel biomarkers and therapeutic targets.

Through a combination of cutting-edge techniques, including advanced microscopy, molecular biology, and bioinformatics, Dr. Huang seeks to gain a deeper understanding of the cellular and molecular processes that drive cancer. This knowledge will ultimately contribute to the development of more effective diagnostic tools and personalized treatment strategies for cancer patients.

林子平 醫師/博士
Tzu-Ping Lin, MD., PhD.

科學顧問 Scientific advisor

✤ Experience

M.D., National Taiwan University
Ph.D. in Institute of Clinical Medicine, National Yang-Ming University


✤ Current Position

Attending Physician, Department of Urology, Taipei Veterans General Hospital

Chief, Division of Female and Pediatric Urology, Department of Urology, Taipei Veterans General Hospital

Associate Professor, Department of Urology, National Yang-Ming University

Chief, Department of Urology, School of Medicine, National Yang Ming Chiao Tung University

✤ Special field

Dr. Lin Tzu-Ping is a distinguished urologist and researcher with extensive contributions to the fields of urological oncology, prostate cancer, and upper urinary tract urothelial carcinoma. His prolific publication record spans over two decades, encompassing more than 100 peer-reviewed articles in high-impact journals, such as The Lancet Oncology, Scientific Reports, and Cancer Research.

Dr. Lin has significantly advanced the understanding of neuroendocrine differentiation in prostate cancer, the clinical utility of prostate health indices, and the role of autophagy in cancer cell survival. His collaborative work includes multinational studies, population-based analyses, and innovations in diagnostic imaging and surgical techniques.

As a scientific counselor, Dr. Lin's expertise offers valuable insights into translational research, clinical trial design, and the development of novel therapeutics for urological malignancies.

廖俊厚 醫師
Chun-Hou Liao MD.,PhD.

科學顧問 Scientific advisor

✤ Experience

M.D., National Taiwan University

Master, Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University

Ph.D. in Nutrition and Food Science, Fu-Jen Catholic University.

✤ Current Position

Dean, College of Medicine, Fu-Jen Catholic University

Superintendent, An-Kang Branch of Cardinal Tien Hospital

Professor, School of Medicine, Fu-Jen Catholic University

✤ Special field

Dr. Liao is a senior urologist and his research focuses on prostate diseases, including prostate cancer, urinary incontinence, and urolithiasis. He has published over 140 professional articles in international journals.

Currently, Professor Liao is the Editor-in-Chief of Urological Science, the official journal of Taiwanese Urological Association. He is also the former president of the Taiwanese Continence Society. In addition, he sits on the editorial boards of the Fu-Jen Journal of Medicine, Tzu Chi Medical Journal, and Sexual Medicine.